Literature DB >> 19072101

Asymptomatic sexually transmitted infections in HIV-infected men who have sex with men: prevalence, incidence, predictors, and screening strategies.

Gunter Rieg1, Roger J Lewis, Loren G Miller, Mallory D Witt, Mario Guerrero, Eric S Daar.   

Abstract

Sexually transmitted infections (STIs) have increased among men who have sex with men (MSM) and are associated with unsafe sex practices, intrinsic morbidity, and enhanced genital shedding and transmission of HIV. Screening for asymptomatic STIs is recommended as part of the HIV prevention efforts, however, optimal screening strategies among HIV-infected MSM have not been well defined. In this study, conducted from April 2004 to September 2006, 212 HIV-infected MSM from two urban HIV clinics were screened for asymptomatic STIs. Testing for Neisseria gonorrhea and Chlamydia trachomatis from pharynx, rectum, and urine, as well as serologic testing for syphilis were performed initially, and then after 6 and 12 months. A self-administered questionnaire was used to assess possible predictors of incident asymptomatic STIs. A cost analysis was performed to assess different screening strategies for detecting incident STIs. The baseline prevalence of STIs was 14% (n = 29; 95% confidence interval [CI] 9%-19%) and the incidence of new infections was 20.8 cases per 100 person years (95% CI 14.8-28.4 cases per 100 person years). Younger age, higher CD4 cell count, and marijuana use were associated with increased risk of acquiring an asymptomatic STI. The laboratory cost to detect one positive STI did not significantly differ between once- and twice-yearly screening. However, almost half of all incident STIs were detected at the 6-month screening visit, potentially resulting in an increased duration of infectivity if these cases remained undiagnosed. In conclusion, prevalent and incident asymptomatic STIs are common among HIV-infected MSM. Our data support current Center for Disease Control and Prevention STI guidelines that recommend routine screening at increased frequency for HIV-infected MSM.

Entities:  

Mesh:

Year:  2008        PMID: 19072101      PMCID: PMC2929381          DOI: 10.1089/apc.2007.0240

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  19 in total

1.  Pharyngeal neisseria gonorrhoeae: coloniser or pathogen?

Authors:  J Wallin; M S Siegel
Journal:  Br Med J       Date:  1979-06-02

2.  Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions.

Authors:  H W Chesson; S D Pinkerton
Journal:  J Acquir Immune Defic Syndr       Date:  2000-05-01       Impact factor: 3.731

3.  Asymptomatic urethritis and detection of HIV-1 RNA in seminal plasma.

Authors:  A J Winter; S Taylor; J Workman; D White; J D Ross; A V Swan; D Pillay
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

Review 4.  The lifetime cost of current human immunodeficiency virus care in the United States.

Authors:  Bruce R Schackman; Kelly A Gebo; Rochelle P Walensky; Elena Losina; Tammy Muccio; Paul E Sax; Milton C Weinstein; George R Seage; Richard D Moore; Kenneth A Freedberg
Journal:  Med Care       Date:  2006-11       Impact factor: 2.983

5.  Increased sensitivity of DNA amplification testing for the detection of pharyngeal gonorrhea in men who have sex with men.

Authors:  Kimberly Page-Shafer; Alison Graves; Charlotte Kent; Joyce E Balls; Virginia M Zapitz; Jeffrey D Klausner
Journal:  Clin Infect Dis       Date:  2001-12-07       Impact factor: 9.079

6.  Evaluation of ligase chain reaction for the non-cultural detection of rectal and pharyngeal gonorrhoea in men who have sex with men.

Authors:  H Young; K Manavi; A McMillan
Journal:  Sex Transm Infect       Date:  2003-12       Impact factor: 3.519

7.  Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2003-07-18

8.  Validation of roche COBAS Amplicor assay for detection of Chlamydia trachomatis in rectal and pharyngeal specimens by an omp1 PCR assay.

Authors:  N A Lister; S N Tabrizi; C K Fairley; S Garland
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

9.  Urine-based asymptomatic urethral gonorrhea and chlamydia screening and sexual risk-taking behavior in men who have sex with men in greater Boston.

Authors:  Christopher J Russell; Sarit A Golub; Daniel E Cohen; Kenneth H Mayer
Journal:  AIDS Patient Care STDS       Date:  2007-03       Impact factor: 5.078

10.  Screening for Neisseria gonorrhoeae and Chlamydia trachomatis in men who have sex with men at male-only saunas.

Authors:  N A Lister; A Smith; S Tabrizi; P Hayes; N A Medland; S Garland; C K Fairley
Journal:  Sex Transm Dis       Date:  2003-12       Impact factor: 2.830

View more
  40 in total

1.  Gonorrhea and Chlamydia Case Detection Increased When Testing Increased in a Multisite US HIV Cohort, 2004-2014.

Authors:  Julia R Raifman; Kelly A Gebo; William Christopher Mathews; Philip Todd Korthuis; Khalil G Ghanem; Judith A Aberg; Richard D Moore; Ank E Nijhawan; Anne K Monroe; Stephen A Berry
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-01       Impact factor: 3.731

2.  Substance Abuse, Hepatitis C, and Aging in HIV: Common Cofactors that Contribute to Neurobehavioral Disturbances.

Authors:  Randi Melissa Schuster; Raul Gonzalez
Journal:  Neurobehav HIV Med       Date:  2012-02-16

3.  New syphilis cases and concurrent STI screening in a southeastern U.S. HIV clinic: a call to action.

Authors:  Cynthia W Baffi; Inmaculada Aban; James H Willig; Mayank Agrawal; Michael J Mugavero; Laura H Bachmann
Journal:  AIDS Patient Care STDS       Date:  2010-01       Impact factor: 5.078

4.  Incidence of and risk factors for type-specific anal human papillomavirus infection among HIV-positive MSM.

Authors:  Alexandra L Hernandez; Jimmy T Efird; Elizabeth A Holly; J Michael Berry; Naomi Jay; Joel M Palefsky
Journal:  AIDS       Date:  2014-06-01       Impact factor: 4.177

5.  Brief Report: Gonorrhea and Chlamydia Testing Increasing but Still Lagging in HIV Clinics in the United States.

Authors:  Stephen A Berry; Khalil G Ghanem; William Christopher Mathews; Philip Todd Korthuis; Baligh R Yehia; Allison L Agwu; Christoph U Lehmann; Richard D Moore; Sara L Allen; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2015-11-01       Impact factor: 3.731

6.  Erectile Dysfunction Medication Prescription: STI and Risk Behavior in Men with HIV.

Authors:  Jose Pablo Heudebert; Ashutosh Tamhane; Greer A Burkholder; Jodie Dionne-Odom
Journal:  J Sex Med       Date:  2019-03-26       Impact factor: 3.802

7.  Dual rapid test for HIV and syphilis: A laboratory evaluation of the diagnostic accuracy of the Standard Q HIV/Syphilis Combo Test.

Authors:  Claire C Bristow; Silver Keith Vargas Rivera; Lourdes B Ramos Cordova; Luz Jazmín Qquellon Palacios; Kelika A Konda; Jeffrey D Klausner
Journal:  Diagn Microbiol Infect Dis       Date:  2018-11-24       Impact factor: 2.803

8.  Elevated HIV and STI Prevalence and Incidence Among Methamphetamine-Using Men Who Have Sex With Men in Los Angeles County.

Authors:  Cathy J Reback; Jesse B Fletcher
Journal:  AIDS Educ Prev       Date:  2018-08

9.  Highly active antiretroviral therapy is associated with decreased incidence of sexually transmitted diseases in a Taiwanese HIV-positive population.

Authors:  Shu-Hsing Cheng; Chin-Hui Yang; Yu-Mei Hsueh
Journal:  AIDS Patient Care STDS       Date:  2013-02-26       Impact factor: 5.078

10.  Denial of risk behavior does not exclude asymptomatic anorectal sexually transmitted infection in HIV-infected men.

Authors:  Edward R Cachay; Amy Sitapati; Joseph Caperna; Kellie Freeborn; Joseph T Lonergan; Edward Jocson; William C Mathews
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.